Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The Pharmaceuticals market in Hong Kong has been experiencing steady growth in recent years.
Customer preferences: Hong Kong residents have a strong preference for Western medicine, which has driven the growth of the Pharmaceuticals market. This is due to the perception that Western medicine is more effective and reliable than traditional Chinese medicine. Additionally, an aging population has increased demand for pharmaceutical products, particularly for chronic disease management.
Trends in the market: One trend in the Hong Kong Pharmaceuticals market is an increase in demand for generic drugs. This is due to the government's efforts to reduce healthcare costs and promote the use of affordable drugs. Another trend is the growing popularity of e-commerce platforms for purchasing pharmaceutical products. This is driven by the convenience and accessibility of online shopping, particularly for those who may have difficulty traveling to physical stores.
Local special circumstances: Hong Kong's status as a global financial hub has attracted many multinational pharmaceutical companies to establish a presence in the region. This has led to increased competition and innovation in the market. Additionally, the government has implemented policies to promote the development of the local pharmaceutical industry, particularly in the areas of research and development.
Underlying macroeconomic factors: Hong Kong's strong economic growth and high per capita income have contributed to the growth of the Pharmaceuticals market. Additionally, the government's commitment to healthcare infrastructure and investment in research and development have created a favorable environment for the industry. However, the ongoing political instability and uncertain future relationship with Mainland China may pose challenges for the market in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)